Dermatopharmacokinetic bioequivalence guidance "has had a significant number of questions in the last few months," Winkle said. "We are going back and doing some research...and we will take another look at the testing method and determine what the guidance really needs to say." The draft guidance was published in 1998 (1"The Pink Sheet" June 29, 1998, p. 24)
You may also be interested in...
Dermatopharmacokinetics, assessed by "skin stripping," would be acceptable as a primary means for establishing bioequivalence for most topical dermatologic drugs, an FDA draft guidance states.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials